Physician profile
Daniel Ethan Boxer
NPI 1043479090
$3,545.61
in general payments reported to CMS, 2019-2025
40 companies · $58.48 in 2025
The $58.48 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $727 · 2020: $190 · 2021: $75.26 · 2022: $65.27 · 2023: $633 · 2024: $1,797 · 2025: $58.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,478 · Education: $10.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,478.41 |
| Education | $10.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $336.41 | 2019-2024 | Reblozyl, Pomalyst |
| Novartis Pharmaceuticals Corporation | $330.59 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $243.92 | 2019-2024 | Keytruda |
| Pfizer INC. | $222.43 | 2023-2024 | |
| Abbvie INC. | $201.00 | 2019-2024 | Venclexta |
| Lilly USA, LLC | $191.38 | 2019-2024 | Jaypirca, Verzenio, Retevmo |
| Array Biopharma INC | $158.49 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Glaxosmithkline, LLC. | $153.65 | 2023-2025 | Ojjaara, Jemperli, Shingrix |
| Astrazeneca Pharmaceuticals LP | $149.48 | 2019-2024 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $148.45 | 2019-2024 | Opdivo |
| Genentech USA, INC. | $129.91 | 2019-2024 | Venclexta, Tecentriq, Gavreto |
| Janssen Biotech, INC. | $122.77 | 2019-2024 | Darzalex, Carvykti, Tecvayli |
| Mirati Therapeutics, INC. | $120.04 | 2023-2024 | Krazati |
| Eisai INC. | $99.41 | 2023-2024 | |
| Amgen INC. | $94.56 | 2019-2023 | Lumakras |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Boxer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.